Skip to main content
SpringerLink
Log in

Mesenchymal Stromal Cell (MSC) Therapy for Crohn’s Disease

  • Chapter
  • First Online:
Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation

  • 1569 Accesses

Abstract

Promising results of MSCs infusion for GI graft versus host disease and fistulizing Crohn’s Disease (CD) have been published. Treatment of Inflammatory Bowel Disease (IBD) requires a comprehensive treatment approach to maintain symptomatic control, improve health-related quality of life measures, and minimize complications from the disease. In this chapter, we will discuss the role of cellular therapies in Crohn’s disease. Success of these phase I, II and III trials have set the stage for usage of this novel treatment in combination with other therapies for CD

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kappelman MD et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907–13.

    Article  PubMed  Google Scholar 

  2. Hanauer S. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12(supplement 1):S3–9.

    Article  PubMed  Google Scholar 

  3. Peyrin-Biroulet L, Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(8):870–9.

    Article  PubMed  CAS  Google Scholar 

  4. Garcia-Bosch O, Ricart E, Panes J. Review article: stem cell therapies for inflammatory bowel disease – efficacy and safety. Aliment Pharmacol Ther. 2010;32(8):939–52.

    Article  PubMed  CAS  Google Scholar 

  5. Ciccocioppo R et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut. 2011;60(6):788–98.

    Article  PubMed  Google Scholar 

  6. Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–17.

    Article  PubMed  Google Scholar 

  7. Parashette KR, Makam RC, Cuffari C. Infliximab therapy in pediatric Crohn’s disease: a review. Clin Exp Gastroenterol. 2010;3:57–63.

    Article  PubMed  CAS  Google Scholar 

  8. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28(2):255–81. vii.

    Article  PubMed  CAS  Google Scholar 

  9. Lazarus HM et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 1995;16(4):557–64.

    PubMed  CAS  Google Scholar 

  10. Le Blanc K et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57(1):11–20.

    Article  PubMed  Google Scholar 

  11. Le Blanc K et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579–86.

    Article  PubMed  Google Scholar 

  12. Bartholomew A et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30(1):42–8.

    Article  PubMed  Google Scholar 

  13. Di Nicola M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838–43.

    Article  PubMed  Google Scholar 

  14. Zappia E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005;106(5):1755–61.

    Article  PubMed  CAS  Google Scholar 

  15. Mohseny AB, Hogendoorn PCW. Mesenchymal tumors: when stem cells go mad. Stem Cells. 2011;29:397–403.

    Article  PubMed  CAS  Google Scholar 

  16. Halme L et al. Family and twin studies in inflammatory bowel disease. World J Gastroenterol. 2006;12(23):3668–72.

    PubMed  Google Scholar 

  17. Sewell GW, Marks DJ, Segal AW. The immunopathogenesis of Crohn’s disease: a three-stage model. Curr Opin Immunol. 2009;21(5):506–13.

    Article  PubMed  CAS  Google Scholar 

  18. Barrett JC et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40(8):955–62.

    Article  PubMed  CAS  Google Scholar 

  19. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1756–67.

    Article  PubMed  CAS  Google Scholar 

  20. Mannon PJ et al. Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production. Gut. 2011;60(4):449–55.

    Article  PubMed  CAS  Google Scholar 

  21. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009;136(1):65–80.

    Article  PubMed  Google Scholar 

  22. Porter CK et al. Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology. 2008;135(3):781–6.

    Article  PubMed  Google Scholar 

  23. Chow J, Tang H, Mazmanian SK. Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr Opin Immunol. 2011;23(4):473–80.

    Article  PubMed  CAS  Google Scholar 

  24. Garrett WS et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell. 2009;16(3):208–19.

    Article  PubMed  CAS  Google Scholar 

  25. Garrett WS et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell. 2007;131(1):33–45.

    Article  PubMed  CAS  Google Scholar 

  26. Garrett WS et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe. 2010;8(3):292–300.

    Article  PubMed  CAS  Google Scholar 

  27. Marks DJ et al. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn’s disease. Am J Gastroenterol. 2009;104(1):117–24.

    Article  PubMed  CAS  Google Scholar 

  28. Reeves EP et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature. 2002;416(6878):291–7.

    Article  PubMed  CAS  Google Scholar 

  29. Gonzalez-Rey E et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58(7):929–39.

    Article  PubMed  CAS  Google Scholar 

  30. Yabana T et al. Enhancing epithelial engraftment of rat mesenchymal stem cells restores epithelial barrier integrity. J Pathol. 2009;218(3):350–9.

    Article  PubMed  CAS  Google Scholar 

  31. Valcz G et al. The role of the bone marrow derived mesenchymal stem cells in colonic epithelial regeneration. Pathol Oncol Res. 2011;17(1):11–6.

    Article  PubMed  CAS  Google Scholar 

  32. Powell DW et al. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol. 1999;277(1 Pt 1):C1–9.

    PubMed  CAS  Google Scholar 

  33. Brittan M et al. Bone marrow derivation of pericryptal myofibroblasts in the mouse and human small intestine and colon. Gut. 2002;50(6):752–7.

    Article  PubMed  CAS  Google Scholar 

  34. Brittan M, Wright NA. Stem cell in gastrointestinal structure and neoplastic development. Gut. 2004;53(6):899–910.

    Article  PubMed  CAS  Google Scholar 

  35. Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol. 2008;19(3):294–308.

    Article  PubMed  CAS  Google Scholar 

  36. Oyama Y et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease. Gastroenterology. 2005;128(3):552–63.

    Article  PubMed  Google Scholar 

  37. Cassinotti A et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn’s disease. Gut. 2008;57(2):211–7.

    Article  PubMed  CAS  Google Scholar 

  38. Group BaMTfE. Autologous stem cell transplantation for Crohn’s disease: ASTIC Autologous Stem Cell Transplantation for Crohn’s Disease. ClinicalTrials.gov, 2006(NCT00297193). 2006.

    Google Scholar 

  39. Burt RK et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood. 2010;116(26):6123–32.

    Article  PubMed  CAS  Google Scholar 

  40. Kotlarz D et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology. 2012;143(2):347–55.

    Article  PubMed  CAS  Google Scholar 

  41. Groux H et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389(6652):737–42.

    Article  PubMed  CAS  Google Scholar 

  42. Desreumaux P et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn’s disease. Gastroenterology. 2012;143(5):1207–1217.e2.

    Article  PubMed  CAS  Google Scholar 

  43. Onken JE, Norata GD, Hanson J, Pandak M, Custer L. Successful outpatient treatment of refractory Crohn’s disease using adult mesenchymal stem cells. In: American College of Gastroenterology annual meeting, Las Vegas; 2006.

    Google Scholar 

  44. Liang J et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. Gut. 2012;61(3):468–9.

    Article  PubMed  Google Scholar 

  45. Therapeutics O. A phase III, multicenter, placebo-controlled, randomized, double-blind study to evaluate the safety and efficacy of Prochymal[tm] (ex vivo cultured adult human mesenchymal stem cells)intravenous infusion for the induction of remission in subjects experiencing treatment-refractory moderate-to-severe Crohn’s disease. ClinicalTrials.gov, 2010(NCT00482092). 2010.

    Google Scholar 

  46. Theraputics O. Evaluation of PROCHYMAL for treatment-refractory moderate-to-severe Crohn’s disease. ClinicalTrials.gov, 2010(NCT01233960). 2010.

    Google Scholar 

  47. Osiris Therapeutics I. Osiris resumes enrollment in stem cell trial for crohn’s disease following positive interim analysis. 2010.

    Google Scholar 

  48. Duijvestein M et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut. 2010;59(12):1662–9.

    Article  PubMed  Google Scholar 

  49. Garcia-Olmo D et al. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48(7):1416–23.

    Article  PubMed  Google Scholar 

  50. Garcia-Olmo D et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52(1):79–86.

    Article  PubMed  Google Scholar 

  51. Le Blanc K et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363(9419):1439–41.

    Article  PubMed  Google Scholar 

  52. Martin PJU, Uberti JP, Soiffer RJ, Klingemann H, Waller EK, Daly AS, et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase iii trial in GVHD. Biol Blood Marrow Transplant. 2010;16:S169–70.

    Article  Google Scholar 

  53. Prasad VK et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant. 2011;17(4):534–41.

    Article  PubMed  CAS  Google Scholar 

  54. Ringden O, Le Blanc K. Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Pract Res Clin Haematol. 2011;24(1):65–72.

    Article  PubMed  CAS  Google Scholar 

  55. Chamberlain G et al. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25(11):2739–49.

    Article  PubMed  CAS  Google Scholar 

  56. Dinesen L, Wang A, Vianello F. Mesenchymal stem cells administered via novel selective mesenteric artery cannulation for the treatment of severe refractory Crohn’s disease. J Crohns Colitis. 2010;3:S51e2.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Children’s Mercy Hospital, 2401 Gillham Rd, Kansas City, MO, 64108, USA

    Jignesh Dalal M.D.

Authors
  1. Jignesh Dalal M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jignesh Dalal M.D. .

Editor information

Editors and Affiliations

  1. Chinese Academy of Medical Sciences and Peking Union Medical College, Center of Excellence in Tissue Engineering, Institute of Basic Medical Sciences and School of Basic Medicine, 5 Dong Dan San Tiao, Beijing, 100005, China, People's Republic

    Robert Chunhua Zhao

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Dalal, J. (2013). Mesenchymal Stromal Cell (MSC) Therapy for Crohn’s Disease. In: Zhao, R. (eds) Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6716-4_15

Download citation

Publish with us

Policies and ethics

Search

Navigation